NTLA (Intellia Therapeutics) LT-Debt-to-Total-Asset: 0.08 (As of Mar. 2026)

What is Intellia Therapeutics LT-Debt-to-Total-Asset?

Intellia Therapeutics NTLA +1.89% 71 LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus rates NTLA with a GF Score™ of 71/100 and a GF Value™ of $20.57 (Modestly Undervalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Intellia Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.08.

Intellia Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.08) to Mar. 2026 (0.08). It may suggest that Intellia Therapeutics is progressively becoming less dependent on debt to grow their business.

Intellia Therapeutics (NAS:NTLA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Intellia Therapeutics LT-Debt-to-Total-Asset Related Terms

Intellia Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics LT-Debt-to-Total-Asset Chart

Intellia Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.08

0.07

0.16

0.08

Intellia Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.08	0.08	0.08	0.08	0.08

71GF Score

Intellia Therapeutics Inc NTLA

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Intellia Therapeutics LT-Debt-to-Total-Asset Calculation

Intellia Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	66.849	/	842.127
	=	0.08

Intellia Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	61.395	/	758.779
	=	0.08

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.08 mean?

Intellia Therapeutics (NTLA) has a LT-Debt-to-Total-Asset of 0.08 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Intellia Therapeutics and its competitors.

Is Intellia Therapeutics' LT-Debt-to-Total-Asset too high?

Intellia Therapeutics' current LT-Debt-to-Total-Asset is 0.08. Overall, Intellia Therapeutics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Intellia Therapeutics' LT-Debt-to-Total-Asset compare to MLYS and VCEL?

Intellia Therapeutics' LT-Debt-to-Total-Asset of 0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current LT-Debt-to-Total-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Intellia Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.57, compared to a current price of $17.56 — trading 14.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.08. Intellia Therapeutics' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $17.56 is trading 14.6% below its estimated GF Value™ of $20.57. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

LT-Debt-to-Total-Asset: 0.08
GF Value™: $20.57 vs. price of $17.56 (14.6% below fair value)
GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies MLYS VCEL NRIX PHVS BHVN IMNM AGIO ABCL KOD SLS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 0JBU:UK 38I:Germany

Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website https://www.intelliatx.com

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

71GF Score

Get the complete analysis for NTLA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.56

Price

$20.57

GF Value

View NTLA Analysis

See LT-Debt-to-Total-Asset data for all stocks →